Replies to post #8695 on Biotech Values

[DewDiligence]

Thanks, walldiver! Some questions and comments:

1. How much does it cost to get the single-issue copy of BM that features DNDN?

2. What is the info in the link at the bottom that does not work properly? Can we substitute something from another source such as DNDN’s own website?

3. I think links to the Wells Fargo webcast and the ASCO-timed DNDN CC should be added to your file. Do you agree?

[Biowatch]

walldiver, could you add a basic reference to your final "read me" file, such as:

http://www.cancer.gov/cancertopics/types/prostate

and a definition of "Gleason score" such as:

http://www.acor.org/cnet/glossary/45696.html

>>Gleason score

Pronunciation: (GLEE-sun)

Definition: A system of grading prostate cancer cells based on how they look under a microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A low Gleason score means the cancer cells are similar to normal prostate cells and are less likely to spread; a high Gleason score means the cancer cells are very different from normal and are more likely to spread.
<<

Thanks.

[walldiver]

Updated DNDN Read Me First file

Provenge potential market
http://tinyurl.com/6yv4y
http://tinyurl.com/3k857

FDA Prostate Cancer Workshop 6/04 (change to Transcript2.pdf and 3.pdf for continuation)
http://www.fda.gov/cder/drug/cancer_endpoints/ProstateTranscript1.pdf

9901 trial Gleason score breakdown (we now know that 4 out of 5 surviving placebo arm patients crossed over to receive salvage Provenge after progression)
http://tinyurl.com/5v6xy

ASCO Prostate Cancer presentation Dr. Eric Small 2/05
http://tinyurl.com/4b7to

ASCO Prostate discussions Feb 2005
http://tinyurl.com/5hykx
http://tinyurl.com/4ssxf
http://tinyurl.com/4njwt

And finally, Biotech Monthly has the most comprehensive background info for Dendreon, far more than any brokerage house. The Nov 2004 issue would be available for a single-issue purchase, approx 40 pages are devoted to Dendreon. Price for single issue is in the $60 range. The issue covers the Provenge mechanism of action, trial history, and pipeline.
http://www.biotechMonthly.com/archive_2004.htm

Basic facts about prostate cancer
http://www.cancer.gov/cancertopics/types/prostate
http://www.acor.org/cnet/glossary/45696.html